Thierry Bernard, Senior Vice President, Molecular Diagnostics Business Area, leads QIAGEN’s growing presence in diagnostic solutions for healthcare. Mr. Bernard joined the QIAGEN team in February 2015 from bioMérieux, where he served in roles of increasing responsibility for 15 years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. Prior to joining bioMérieux, he served in management roles in multiple international environments. Mr. Bernard has served as a member of the Boards of Directors of several U.S. companies. He has earned degrees from Sciences Po (Paris), Harvard Business School, London School of Economics and the College of Europe and is a member of French Foreign Trade Advisors.
Donald B. Hawthorne is the President & CEO of Daktari Diagnostics.
Peter Kaspar has more than 30 years of experience in the life sciences and diagnostics industries. He worked for bioMérieux from 2006 to 2011 as Head of the Microbiology unit and Head of Global Research and Development. In 1980, Peter Kaspar joined Boehringer Mannheim GmbH (which was acquired by Roche in 1998) where, until 2006, he held several management positions in R&D, business development, and strategy in Germany, Mexico, and the United States. From 2005 to 2006, Peter led the technology and business development of FIND, a non-profit organization based in Geneva that enables the development and delivery of diagnostic tests for diseases of poverty. He has served on the board of several biotechnology companies in the United States and Germany. Peter Kaspar was trained in biochemistry and medicine at the universities of Münster, Berlin (Germany) and Lille (France).
David M. Rubin, Ph.D. is a Managing Director in Merck’s Global Health Innovation fund with a primary focus area on precision medicine. David has invested in molecular diagnostics, point-of-care diagnostics, imaging, and therapeutic device companies that address unmet needs in oncology, infectious disease, neurology, and cardiovascular disease. David holds board seats at OpGen, Daktari Diagnostics, electroCore, and Prophecy; and is a board observer at Asuragen and Genome Dx. David joined Merck in 2007 as Director of Franchise and Portfolio Management. His primary responsibilities were to oversee the operational support of all MRL disease area franchises and provide portfolio management support to MRL Oncology, including the development of franchise strategies, scenario planning, and portfolio valuation. David joined Merck from Cognia Corporation where he was CEO and President, and helped to build it into one of the pioneer bioinformatics products company. Previously, David was at The Wilkerson Group/IBM Global Services in a Strategic Management position supporting pharma, biotech, and diagnostics companies. David holds a Ph.D. from Temple University in Molecular Biology and a BA from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University.
Aaron Sandoski currently serves as the managing director at Norwich Ventures. Previously, Aaron worked for DEKA, the engineering think tank of Dean Kamen, where he helped develop partnerships and formulate business plans for emerging technologies. Aaron began his career as a consultant at McKinsey & Company, where he advised healthcare clients ranging from leading medical device companies to a rural hospital system. Aaron earned an M.B.A. from Harvard Business School and graduated from Dartmouth College with a double A.B. in Chemistry and Economics.